---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-022715"
form_type: "8-K"
ticker: "VYCO"
cik: "0001424768"
company_name: "VYCOR MEDICAL INC"
filed_at: "2025-08-08T23:59:59+00:00"
generated_at: "2026-05-17T16:15:54.568725+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vycor Medical Q2 revenue up 22% to $496K; VBAS division drives growth with new international distribution

## Summary
- Q2 total revenue $496,353 (+22% YoY); Vycor Medical (VBAS) up 24% to $481,788, led by international markets.
- GAAP operating profit Q2 $51,146; non-GAAP operating profit $84,481, up from $31,859 in Q2 2024.
- Gross margin fell to 83% from 91% due to validation/shipping costs of new production and sales mix.
- Entered new distribution agreements for France and Spain during H1 2025, targeting key international markets.
- Two new peer-reviewed VBAS clinical papers published in Q2; total now 48. NovaVision study validates NeuroEyeCoach for home/clinic.

## SEC filing metadata
- accession: 0001641172-25-022715
- form_type: 8-K
- ticker: VYCO
- cik: 0001424768
- company_name: VYCOR MEDICAL INC
- filed_at: 2025-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1424768/000164117225022715/0001641172-25-022715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1424768/000164117225022715/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-022715
- JSON: https://secwatch.observer/filing/0001641172-25-022715.json
- Plain text: https://secwatch.observer/filing/0001641172-25-022715.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.